Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Beáta-Mária BenkőUniversity Pharmacy Department of Pharmacy Administration, Semmelweis University, Hőgyes Endre u. 7-9, 1092 Budapest, Hungary.ORCID 0000-0002-3608-6219
Bálint-Imre SzabóEgis Pharmaceuticals Plc., R&D Directorate, 1475 Budapest, Hungary.
Szabina KádárDepartment of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3, 1111 Budapest, Hungary.
Edina SzabóDepartment of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3, 1111 Budapest, Hungary.ORCID 0000-0001-9616-5122
Gergő TóthDepartment of Pharmaceutical Chemistry, Semmelweis University, Hőgyes Endre u. 7-9, 1092 Budapest, Hungary.ORCID 0000-0001-5341-319X
Lajos SzenteCycloLab Cyclodextrin Research & Development Laboratory Ltd., Illatos út 7, 1097 Budapest, Hungary.
Péter Tonka-NagyEgis Pharmaceuticals Plc., R&D Directorate, 1475 Budapest, Hungary.
Romána ZelkóUniversity Pharmacy Department of Pharmacy Administration, Semmelweis University, Hőgyes Endre u. 7-9, 1092 Budapest, Hungary.ORCID 0000-0002-5419-9137
István SebeUniversity Pharmacy Department of Pharmacy Administration, Semmelweis University, Hőgyes Endre u. 7-9, 1092 Budapest, Hungary.
Funding
National Research, Development, and Innovation Office, Hungary NKFIH FK 146930New National Excellence Program of the Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund EKÖP-2024-128University Research Fellowship Programme of the Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund EKÖP-24-4-I-BME-127
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Development of Low-Dose Disulfiram Rectal Suppository Intended for Application in Post-Treatment Lyme Disease Syndrome. · full record | OpenQuestion